Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gross Profit (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Gross Profit for 5 consecutive years, with $52.5 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 37.87% to $52.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $170.3 million through Dec 2025, up 45.83% year-over-year, with the annual reading at $170.3 million for FY2025, 45.83% up from the prior year.
  • Gross Profit for Q4 2025 was $52.5 million at Rhythm Pharmaceuticals, up from $45.8 million in the prior quarter.
  • The five-year high for Gross Profit was $52.5 million in Q4 2025, with the low at -$9.1 million in Q4 2022.
  • Average Gross Profit over 5 years is $18.1 million, with a median of $18.5 million recorded in 2023.
  • Peak annual rise in Gross Profit hit 6241.61% in 2022, while the deepest fall reached 674.07% in 2022.
  • Over 5 years, Gross Profit stood at $1.6 million in 2021, then plummeted by 674.07% to -$9.1 million in 2022, then skyrocketed by 331.39% to $21.0 million in 2023, then surged by 81.15% to $38.0 million in 2024, then soared by 37.87% to $52.5 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $52.5 million, $45.8 million, and $43.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.